Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

[1]  P. O S I T I O N S T A T E M E N T,et al.  Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.

[2]  P. Weiden,et al.  Long-Term Changes in Weight and Plasma Lipids during Maintenance Treatment with Ziprasidone , 2008, Neuropsychopharmacology.

[3]  S. Saha,et al.  A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? , 2007, Archives of general psychiatry.

[4]  A. Gotto,et al.  HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. , 2007, The New England journal of medicine.

[5]  S. Likhitsathian,et al.  Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study , 2007, BMC psychiatry.

[6]  S. Grundy,et al.  Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. , 2007, The American journal of cardiology.

[7]  K. Houseknecht,et al.  Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects , 2007, Neuropsychopharmacology.

[8]  J. Bobes,et al.  Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study , 2007, Schizophrenia Research.

[9]  D. Goff,et al.  Glucose metabolism in patients with schizophrenia treated with olanzapine or quetiapine: a frequently sampled intravenous glucose tolerance test and minimal model analysis. , 2006, The Journal of clinical psychiatry.

[10]  J. Shaw,et al.  Metabolic syndrome—a new world‐wide definition. A Consensus Statement from the International Diabetes Federation , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[11]  J. Peuskens,et al.  Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication , 2006, Schizophrenia Research.

[12]  T. Mjörndal,et al.  High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia , 2006, International clinical psychopharmacology.

[13]  Richard W Morris,et al.  Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. , 2005, Archives of internal medicine.

[14]  J. Lieberman,et al.  A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls , 2005, Schizophrenia Research.

[15]  J. Lieberman,et al.  Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III , 2005, Schizophrenia Research.

[16]  John A Spertus,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Executive Summary , 2005, Critical pathways in cardiology.

[17]  R. Krauss,et al.  Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement , 2005, Current opinion in cardiology.

[18]  Fernando Costa,et al.  Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.

[19]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[20]  D. Goff,et al.  Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. , 2005, The Journal of clinical psychiatry.

[21]  L. Bouter,et al.  An exploratory analysis of criteria for the metabolic syndrome and its prediction of long-term cardiovascular outcomes: the Hoorn study. , 2005, American journal of epidemiology.

[22]  Richard Kahn,et al.  The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. , 2005, Diabetes care.

[23]  R. Kahn,et al.  The metabolic syndrome: time for a critical appraisal , 2005, Diabetologia.

[24]  G. Reaven.  The metabolic syndrome: requiescat in pace. , 2005, Clinical chemistry.

[25]  M. Järvelin,et al.  A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. , 2005, The Journal of clinical psychiatry.

[26]  G. Remington,et al.  Characterizing Coronary Heart Disease Risk in Chronic Schizophrenia: High Prevalence of the Metabolic Syndrome , 2004, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[27]  C. Koro,et al.  The effects of antipsychotic therapy on serum lipids: a comprehensive review , 2004, Schizophrenia Research.

[28]  John M Davis,et al.  Physical health monitoring of patients with schizophrenia. , 2004, The American journal of psychiatry.

[29]  J. Racoosin,et al.  Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. , 2004, Diabetes care.

[30]  E. Ford.  The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. , 2004, Atherosclerosis.

[31]  R. Holt,et al.  Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia , 2004, British Journal of Psychiatry.

[32]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Circulation.

[33]  Claude Lenfant,et al.  Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[34]  Tracey McLaughlin,et al.  Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant , 2003, Annals of Internal Medicine.

[35]  P. Macfarlane,et al.  Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study , 2003, Circulation.

[36]  H. Nasrallah,et al.  Medical Illness and Schizophrenia , 2003 .

[37]  Nancy R Cook,et al.  C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.

[38]  J. Cauley,et al.  The prediction of visceral fat by dual-energy X-ray absorptiometry in the elderly: a comparison with computed tomography and anthropometry , 2002, International Journal of Obesity.

[39]  Jonathan M. Meyer.  A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. , 2002, The Journal of clinical psychiatry.

[40]  J M Dekker,et al.  Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: The Hoorn Study. , 2001, JAMA.

[41]  R. Bergman,et al.  Insulin secretion, obesity, and potential behavioral influences: results from the Insulin Resistance Atherosclerosis Study (IRAS) , 2001, Diabetes/metabolism research and reviews.

[42]  R. Troisi,et al.  Diurnal variation in fasting plasma glucose: implications for diagnosis of diabetes in patients examined in the afternoon. , 2000, JAMA.

[43]  H. Hein,et al.  Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study. , 1998, Circulation.

[44]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[45]  G. Reaven.  Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[46]  W. Dixon.  Simplified Estimation from Censored Normal Samples , 1960 .

[47]  N. Unwin,et al.  Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National , 2009 .

[48]  J. Newcomer.  Second-Generation (Atypical) Antipsychotics and Metabolic Effects , 2005, CNS drugs.

[49]  C. Byrne,et al.  Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes , 2005, Diabetologia.

[50]  R. Krauss,et al.  Diagnosis and management of the metabolic syndrome , 2005 .

[51]  J. Lieberman,et al.  The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. , 2003, Schizophrenia bulletin.

[52]  J. Mckenney,et al.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). , 2001, JAMA.

[53]  North American Association for the Study of Obesity , 1991, International journal of obesity.